Replies to post #248756 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Well put! I’m in your camp. There is a deal or deals pending....we just have to watch the pot boil. BP will make so much money on BOM if they throw ipix a bone....it will happen.

Happy thirsty Thursday!

[BooDog]

B-OM $60M upfront plus milestones I'm thinking. This isn't going to be a small trial imo. Protocol could very well be a phase 3/4. Also would not be at all surprised to see an EU partner up pretty quick too once the trial gets its first round of data. Though the data we have to date should be impressive enough to start through that arena. Or maybe they'll do that with brilacidin-UP.

Anyway, the first deal stets IPIX up for the future. Nothing we don't already know. Some just lack the patience and some just shy away from the OTC when things look a bit sketchy. And, naturally, some have hit their stop loss limits, likely long ago. That's just the market we're in today. Show results and get the deal done. Till then, plenty of games afoot. And of course there's the tax loss people, if I were one of those I'd be looking for my 30 days to be done by the EOP meeting with the FDA. It's possible we could still see BTD by then as well.

Message in reply to MackG:

B for OM deal coming soon IMO. FDA mid Dec. EOP2 meeting big deal. Don’t let it be down played. This is an achievement.
K pill coming soon based on 10q. Possible revolutionary complimentary medicine. Go look at the K pre-clinical data. It’s easy to find. Harder to read. But worth the time. Go look at the K phase 2 results. P53 modulation was achieved! Do some reading. Put in the time and see how amazing K could potentially be. The shareholders who believe in the science and the good these medicines could potentially do should be shouting from the digital mountain top. Twitter followers. Instagram and Facebook page. Tell family and friends what they could be investing in at stupid prices IMO. Form a strong base while we shed the weak hands. All just my opinion. I’m sure most of your family and friends are secretly or openly mad at you for telling them about IPIX a while ago. Well it was worth it then and it’s even more worth it now. Lower your cost basis and go start a hobby. JMO. GL

Message in reply to:

Nerby, some investors only see what has happened to the share price. For them, logic is a speck floating on a sea of emotion. I find peace, as you do, resting in knowledge of facts that support the long-range view that you have expressed. When money worries are resolved with a deal(s), the investment dynamic and prevailing attitudes will change.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144609453

There are updates that could be done to Sox's post...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142367628
Such as completing the data for brilacidin and the tox work up for kevetrin. Still a bit to go on that imo.

Message in reply to DaubersUP:

COMPARE FOR YOURSELF - 2012 to 2018 - IPIX $$$

AUGUST 31st 2012 - Closed at .63
September 31st 2012 - Closed at 1.00

In the 10-K released on 10/12/12 I found the below info. Here is link to 10-K (https://www.bamsec.com/filing/154823312000017?cik=1355250)

CASH ON HAND - $27,000
CTIX did not have any major Stock Purchase Agreements at the time! So no funds readily available.

OS as of SEPT 30th 2012 - - 93,124,151 (ABOUT 70 MILLION LESS than now)

They had ZERO CLINICAL trials - just pre-clinical work.

Some notes of accomplishments though:
Jan 2012 - Prurisol Patent Filed
March 2012 - BIDMC Agreement to test Keveterin
May 2012 - Jim Boeheim joined as advisor (lol) Jim is a good man but this was exciting at the time.
June 2012 - IND Meeting with FDA approved to seek section 505(b)(2)
June 2012 - IND approved by FDA to begin Phase 1 trial at Dana Farber and BIDMC for Keveterin
Sept 2012 - Selected Dr. Reddy's Lab to manufacturer P

COMPOUNDS OWNED BY CTIX in 2012: 8 TOTAL
Kevetrin
KM 133
KM 391
KM 277
KM 278
KM 362
KM-3174
KM-732

DESIGNATIONS: June 2012 for Prurisol - 505 (b)(2) Approach

_________________________________________________________________
_________________________________________________________________
FAST FORWARD ----- As of OCT 16 2018 -----------

OCTOBER 16th --- Close - .18
Total OS as of AUG 27th 2018 ----- 161,100,000 shares

Cash on hand: 2.4 Million

Financing in place: 22.3 MILLION available from ASPIRE
Financing in place: 75 Million Shelf Reg
Financing in place: 10 Million from MultiFamily Office

Compounds Owned in 2018:
ADDITIONAL COMPOUNDS OWNED AFTER POLYMEDIX's acquisition: 18 TOTAL
**THIS INCLUDES PATENTS** It also included "SUBSTANTIAL EQUIPMENT ASSETS"
"We are very excited about instantly having a strong antibiotic franchise to complement our already robust pipeline that now contains 18 compounds"

ACCOMPLISHMENTS:
CLINICAL TRIALS: (Daubs summary)
1) PHASE I: A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
(Start: Oct 2012 - End: Feb 2016) SUCCESSFUL

2) PHASE 2B: Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
(Start: Feb 2014 - END: Oct 2014) SUCCESSFUL
***Compared favorably to Daptomycin which is a blockbuster drug

3) PHASE I: Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers
(Start: March 2014 - End: Oct 2014) SUCCESFUL

4) PHASE II: Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis
(Start: Aug 2015 - End: May 2016) SUCCESSFUL

5) PHASE 2B: Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis
(Start: Oct 2016 - End: Dec 2017) TOP LINE WHEN WE PAY CRO

6) PHASE 2: Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer (Brilacidin)
(Start: May 2015 - End: Dec 2017) SUCCESSFUL
MGMT COMMENT:

Quote:
After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.


7) A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
(Start: Feb 2017 - End: Feb 2018) SUCCESSFUL

8) A Phase 2 open label Proof-of-Concept trial evaluating Brilacidin as a new treatment for mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two types of inflammatory bowel disease
(Start: June 2016 - End: June 2017) SUCCESSFUL

DESIGNATIONS FROM THE FDA:
Brilacidin -
1) QIDP Fast Track Designation ABSSSI - Dec 2014
2) Fast track Designation for OM - Nov 2015
***BREAKTHROUGH for B-OM has been applied for! Waiting on FDA - WITHIN NEXT 30 DAYS!
KEVETRIN -
3) Orphan Drug Designation for Ovarian Cancer - July 2015
4) Orphan Drug Designation for Retinoblastoma - Nov 2015
5) Rare Pediatric Disease Designation for Retinoblastoma - Nov 2015
(the case for Silver Spring-based United Therapeutics Corp., which sold a voucher for $350 million in 2015)
*Orphan Drug Designation for Pancreatic Cancer - Jan 2016


Approaching 20 CDA's with Big Pharm and other BIO's!

AUGUST 2018 --- NON-BINDING TERM SHEET SIGNED WITH GLOBAL BP for indications of B-OM and B-IBD!!!!

GOOD LUCK ALL!!!

Message in reply to MackG:

Yes. There will be a deal. Or two. Or more. When a deal is announced, the share price will rise substantially. Until then, I will wait.

I'm not just waiting, I'm still accumulating as I can. And if this does dip under the dime, I want to be ready.